The Experts below are selected from a list of 417606 Experts worldwide ranked by ideXlab platform
John S March - One of the best experts on this subject based on the ideXlab platform.
-
Emotional well being in children and adolescents treated with atomoxetine for attention deficit hyperactivity disorder findings from a patient parent and physician perspective using items from the pediatric adverse event rating scale paers
Child and Adolescent Psychiatry and Mental Health, 2008Co-Authors: Peter M Wehmeier, Alexander Schacht, Susan G Silva, Ralf W Dittmann, Martin Lehmann, John S MarchAbstract:Background The objective of this analysis was to measure changes in items on the Pediatric Adverse Event Rating Scale (PAERS) that relate to Emotional Well-Being of children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) during treatment with atomoxetine for up to 24 weeks from the perspective of the patient, the parent, and the physician.
-
Emotional well being in children and adolescents treated with atomoxetine for attention deficit hyperactivity disorder findings from a patient parent and physician perspective using items from the pediatric adverse event rating scale paers
Child and Adolescent Psychiatry and Mental Health, 2008Co-Authors: Peter M Wehmeier, Alexander Schacht, Susan G Silva, Ralf W Dittmann, Martin Lehmann, John S MarchAbstract:Background The objective of this analysis was to measure changes in items on the Pediatric Adverse Event Rating Scale (PAERS) that relate to Emotional Well-Being of children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) during treatment with atomoxetine for up to 24 weeks from the perspective of the patient, the parent, and the physician.
Peter M Wehmeier - One of the best experts on this subject based on the ideXlab platform.
-
Emotional well being in children and adolescents treated with atomoxetine for attention deficit hyperactivity disorder findings from a patient parent and physician perspective using items from the pediatric adverse event rating scale paers
Child and Adolescent Psychiatry and Mental Health, 2008Co-Authors: Peter M Wehmeier, Alexander Schacht, Susan G Silva, Ralf W Dittmann, Martin Lehmann, John S MarchAbstract:Background The objective of this analysis was to measure changes in items on the Pediatric Adverse Event Rating Scale (PAERS) that relate to Emotional Well-Being of children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) during treatment with atomoxetine for up to 24 weeks from the perspective of the patient, the parent, and the physician.
-
Emotional well being in children and adolescents treated with atomoxetine for attention deficit hyperactivity disorder findings from a patient parent and physician perspective using items from the pediatric adverse event rating scale paers
Child and Adolescent Psychiatry and Mental Health, 2008Co-Authors: Peter M Wehmeier, Alexander Schacht, Susan G Silva, Ralf W Dittmann, Martin Lehmann, John S MarchAbstract:Background The objective of this analysis was to measure changes in items on the Pediatric Adverse Event Rating Scale (PAERS) that relate to Emotional Well-Being of children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) during treatment with atomoxetine for up to 24 weeks from the perspective of the patient, the parent, and the physician.
Alexander Schacht - One of the best experts on this subject based on the ideXlab platform.
-
Emotional well being in children and adolescents treated with atomoxetine for attention deficit hyperactivity disorder findings from a patient parent and physician perspective using items from the pediatric adverse event rating scale paers
Child and Adolescent Psychiatry and Mental Health, 2008Co-Authors: Peter M Wehmeier, Alexander Schacht, Susan G Silva, Ralf W Dittmann, Martin Lehmann, John S MarchAbstract:Background The objective of this analysis was to measure changes in items on the Pediatric Adverse Event Rating Scale (PAERS) that relate to Emotional Well-Being of children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) during treatment with atomoxetine for up to 24 weeks from the perspective of the patient, the parent, and the physician.
-
Emotional well being in children and adolescents treated with atomoxetine for attention deficit hyperactivity disorder findings from a patient parent and physician perspective using items from the pediatric adverse event rating scale paers
Child and Adolescent Psychiatry and Mental Health, 2008Co-Authors: Peter M Wehmeier, Alexander Schacht, Susan G Silva, Ralf W Dittmann, Martin Lehmann, John S MarchAbstract:Background The objective of this analysis was to measure changes in items on the Pediatric Adverse Event Rating Scale (PAERS) that relate to Emotional Well-Being of children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) during treatment with atomoxetine for up to 24 weeks from the perspective of the patient, the parent, and the physician.
Martin Lehmann - One of the best experts on this subject based on the ideXlab platform.
-
Emotional well being in children and adolescents treated with atomoxetine for attention deficit hyperactivity disorder findings from a patient parent and physician perspective using items from the pediatric adverse event rating scale paers
Child and Adolescent Psychiatry and Mental Health, 2008Co-Authors: Peter M Wehmeier, Alexander Schacht, Susan G Silva, Ralf W Dittmann, Martin Lehmann, John S MarchAbstract:Background The objective of this analysis was to measure changes in items on the Pediatric Adverse Event Rating Scale (PAERS) that relate to Emotional Well-Being of children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) during treatment with atomoxetine for up to 24 weeks from the perspective of the patient, the parent, and the physician.
-
Emotional well being in children and adolescents treated with atomoxetine for attention deficit hyperactivity disorder findings from a patient parent and physician perspective using items from the pediatric adverse event rating scale paers
Child and Adolescent Psychiatry and Mental Health, 2008Co-Authors: Peter M Wehmeier, Alexander Schacht, Susan G Silva, Ralf W Dittmann, Martin Lehmann, John S MarchAbstract:Background The objective of this analysis was to measure changes in items on the Pediatric Adverse Event Rating Scale (PAERS) that relate to Emotional Well-Being of children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) during treatment with atomoxetine for up to 24 weeks from the perspective of the patient, the parent, and the physician.
Ralf W Dittmann - One of the best experts on this subject based on the ideXlab platform.
-
Emotional well being in children and adolescents treated with atomoxetine for attention deficit hyperactivity disorder findings from a patient parent and physician perspective using items from the pediatric adverse event rating scale paers
Child and Adolescent Psychiatry and Mental Health, 2008Co-Authors: Peter M Wehmeier, Alexander Schacht, Susan G Silva, Ralf W Dittmann, Martin Lehmann, John S MarchAbstract:Background The objective of this analysis was to measure changes in items on the Pediatric Adverse Event Rating Scale (PAERS) that relate to Emotional Well-Being of children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) during treatment with atomoxetine for up to 24 weeks from the perspective of the patient, the parent, and the physician.
-
Emotional well being in children and adolescents treated with atomoxetine for attention deficit hyperactivity disorder findings from a patient parent and physician perspective using items from the pediatric adverse event rating scale paers
Child and Adolescent Psychiatry and Mental Health, 2008Co-Authors: Peter M Wehmeier, Alexander Schacht, Susan G Silva, Ralf W Dittmann, Martin Lehmann, John S MarchAbstract:Background The objective of this analysis was to measure changes in items on the Pediatric Adverse Event Rating Scale (PAERS) that relate to Emotional Well-Being of children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) during treatment with atomoxetine for up to 24 weeks from the perspective of the patient, the parent, and the physician.